Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non Operating Investment Income: 2018-2021

Historic Non Operating Investment Income for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Dec 2021 value amounting to $6.0 million.

  • Lineage Cell Therapeutics' Non Operating Investment Income rose 378.86% to $6.0 million in Q1 2021 from the same period last year, while for Mar 2021 it was $9.3 million, marking a year-over-year increase of 361.16%. This contributed to the annual value of $6.0 million for FY2021, which is 32.11% up from last year.
  • Lineage Cell Therapeutics' Non Operating Investment Income amounted to $6.0 million in FY2021, which was up 32.11% from $4.6 million recorded in FY2020.
  • Lineage Cell Therapeutics' 5-year Non Operating Investment Income high stood at $6.0 million for FY2021, and its period low was -$2.9 million during FY2019.
  • In the last 3 years, Lineage Cell Therapeutics' Non Operating Investment Income had a median value of $4.6 million in 2020 and averaged $2.6 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Non Operating Investment Income slumped by 350.26% in 2019 and then surged by 257.35% in 2020.
  • Yearly analysis of 4 years shows Lineage Cell Therapeutics' Non Operating Investment Income stood at $1.2 million in 2018, then tumbled by 350.26% to -$2.9 million in 2019, then surged by 257.35% to $4.6 million in 2020, then spiked by 32.11% to $6.0 million in 2021.